Sep 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Boehringer's zongertinib demonstrates promising effectiveness and tolerability in patients with HER2-mutated lung cancer who have undergone prior treatment.
On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC).
On September 11, 2024, Sanofi and Regeneron jointly announced that their pivotal study (ADEPT) of Dupilumab (Dupixent) for the treatment of adult patients with Bullous Pemphigoid (BP).
Sep 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.